Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

被引：216

作者：

Powles, Thomas

O'Donnell, Peter H.

Massard, Christophe

Arkenau, Hendrik-Tobias

Friedlander, Terence W.

Hoimes, Chris

Lee, Jae-Lyun

Ong, Michael

Sridhar, Srikala S.

Vogelzang, Nicholas J.

Fishman, Mayer N.

Zhang, Jingsong

Srinivas, Sandy

Parikh, Jigar

Antal, Joyce

Jin, Xiaoping

Gupta, Ashok Kumar

Hahn, Noah M.

机构：

[1] Queen Mary Univ London, Barts Canc Inst, London, England

[2] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA

[3] Inst Gustave Roussy Canc Ctr, Villejuif, France

[4] Sarah Cannon Res Inst, London, England

[5] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA

[6] Case Western Reserve Univ, Seidman Canc Ctr, Cleveland, OH 44106 USA

[7] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[8] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[9] Princess Margaret Canc Ctr, Toronto, ON, Canada

[10] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Stanford Univ, Stanford, CA 94305 USA

[13] Augusta Univ, Augusta, GA USA

[14] MedImmune, Gaithersburg, MD USA

[15] Johns Hopkins Univ, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期

关键词：

D O I：

10.1200/JCO.2017.35.6_suppl.286

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

286

引用

页数：2